Tracking The Molecular Dynamics of Lineage Switch Under CD19 CAR-T Treatment in Non-KMT2A Rearranged B-ALL Patients

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Abstract 5248: Single-cell multi-omics reveals co-mutation of <i>TP53</i> and epigenetic gene driving myeloid transformation in B-ALL following CAR-T therapy2026
2. 2Chemotherapy selects for myeloid subclones in multiple subtypes of B-cell acute lymphoblastic leukemia2025
3. 3Multiple Lineage Switches in a Pediatric Case With a <i>KMT2A::AFF1</i>‐Positive Acute Lymphoblastic Leukemia: How Cell Plasticity Induces Immunotherapy Failure2025 · 1 citations
4. 4Anti-CD7 CAR T-cell therapy for ultra-high-risk relapsed/refractory T-ALL/lbl: Insights into lineage switch and consolidation strategies2025
5. 5Multilineage involvement in <i>KMT2A</i>‐rearranged B acute lymphoblastic leukaemia: cell‐of‐origin, biology, and clinical implications2024